BioTuesdays
Aravive Logo

HCW ups Aravive PT to $26 from $15

H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $26 from $15 after the company announced successful completion of its Phase 1b trial testing AVB-500 in patients with platinum resistant ovarian...

89bio

BTIG starts 89bio at buy; PT $51

BTIG launched coverage of 89bio (NASDAQ:ETNB) with a “buy” rating and $51 price target. The stock closed at $33.14 on July 22. 89bio is developing BIO89-100, a stabilized fibroblast growth factor 21 (FGF21) analog, for...

Brookline starts MiRagen Therapeutics at buy; PT $6

Brookline Capital Markets initiated coverage of MiRagen Therapeutics (NASDAQ:MGEN) with a “buy” rating and 12-to-18 month price target of $6. The stock closed at $1.02 on July 20. MiRagen is working in hematologic...

BTIG starts Akouos at buy; PT $35

BTIG initiated coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $35 price target. The stock closed at $21.12 on July 20. Akouos is focused on the development of highly specific genetic medicines for hearing loss...

EyeGate Pharmaceuticals

AGP starts EyeGate Pharma at buy; PT $9.50

Alliance Global Partners launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy” rating and price target of $9.50, representing a price-to-sales multiple of eight times based on 2022 revenue estimates...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.